Oncotarget started making publications in 2010. The online biomedical journal is free to access by practitioners and the general public alike as the journal aims to educate and spark a higher interest in fields such as oncology, immunology, pathology, and many other areas of the medical science.
Recently, the online medical journal made a change in pace and announced that it would be publishing issues twice a week instead of the usual speed of once a week. Oncotarget supported its decision with it sire to provide as much data and research updates as possible. The online biomedical journal has been working closely with a wide number of prominent institutions handling archives and indexes in order to make sure that all data provided in their publications is accurate and up to date. Check Oncotarget at scimagojr.com
Oncotarget is published by Impact Journals. The biomedical journal is peer-reviewed and has a few dozen experts in science and medicine working on it to elevate its quality. Oncotarget has two Editors in Chief. One of them is Dr. Andrei V. Gudkov from the Roswell Park Cancer Institute, where he does research in oncology and cardiology.
The other Editor in Chief is Dr. Mikhail Blagosklonny whose primary field is also Oncology. He has been working biogerontology as well, doing research in the area of anti-aging. He is known for his work in TOR signaling and his theory about the drug Rapamycin that might be a way to slow down going to some degree. In fact, Dr. Mikhail Böagosklonny is known the strongest proponent of the idea. The medication is used in treating cancer patient during their therapy.
— Oncotarget (@OncotargetJrnl) December 5, 2017
Dr. Mikhil Blagosklonny also worked at the Roswell Cancer Park Institute from 2009 up until 2016. Before that, he taught at the New York Medical College in his role of an associate professor of medicine. In 2002, Dr. Mikhail Blgosklonny took a job at the Ordway Research Institute where he started researching oncology, but the institute was not able to fund deeper research. That led him to join the Roswell Park Cancer Institute in 2009. He moved on from the establishment to focus on his work at Oncotarget. Listen to Oncotarget podcast on Player.FM.